iSelect Closes Round of Funding on Cancer Drug Discovery Company
Recently iSelect sat down with Immunophotonics CEO Lu Alleruzzo to talk about immunotherapy and innovations in the treatment of cancer.
[iSelect] What does the future look like for Immunophotonics? What can we look forward to?
[Lu] I’m very excited about our future and about next steps as we get closer to our goals and major milestones. We have some non-clinical projects in the pipeline that are already showing some promising results in terms of using our therapy in certain models.
Additionally, we’re thrilled that we’re getting ready to finish the final steps before we can move in the clinic here in the states. In fact, we just signed a contract to finish the final non-clinical development required to file an IND application with FDA; that’s certainly something we look forward to in 2016.
Internationally, we’re gearing up for our South American trial where we’ll be collecting patient data and supporting clinical data for our IND package here in the States. 2016 will be a big year for us.
How has iSelect impacted your growth in the last year?
The first thing I want to do is say thank you to iSelect. They have been great to work with and we really appreciate their support. They’ve done a great job in helping to get our name out there, and have brought capital that has allowed us to move forward in really exciting ways.
We started with iSelect about a year ago and were one of the first companies to come on their platform. iSelect puts in a tremendous amount of resources and personnel to support their portfolio companies. Their interests are certainly aligned with that of their companies and they do everything they can to ensure success.
Click here to learn more about Immunophotonics.